

T: 0131-244 2528 F: 0131-244 2375
E: irene.fazakerley@scotland.gsi.gov.uk

IMMEDIATE MESSAGE TO:

1. Directors of Pharmacy
2. Chief Pharmacists NHS Boards
3. Hospital Pharmacy Managers
4. Medical Directors NHS Boards
5. Chief Executives NHS Boards

2 June 2010

Dear Healthcare Professional,
DRUG ALERT NO 12 – CLASS 2

Please find attached drug safety information from the Medicines and Healthcare products Regulatory agency (MHRA) for onward transmission (see list below).

1. Please could all Directors of Pharmacy forward this alert to:-

- Community Pharmacists
- Hospital Pharmacists
- Chief Pharmacists to forward on to Medicines Information Pharmacists

2. Please could Medical Directors forward this alert to:-

- General Practitioners
- Hospital and Relevant Clinics
- Chief Executives of NHS Boards

Thank you for your co-operation.

Yours sincerely

IRENE FAZAKERLEY
Pharmacy Division



Safeguarding public health

Defective Medicines Report Centre
Market Towers
1 Nine Elms Lane
London
SW8 5NQ
Telephone: +44 (0)20 7084 2574

Fax: +44 (0)20 7084 2676

DRUG ALERT

CLASS 2 MEDICINES RECALL

Action Within 48 Hours

PHARMACY AND EQUIVALENT LEVEL RECALL

Date: 02 June 2010

EL (10)A/12

Our Ref: MDR 40-02/10

Dear Healthcare Professional,

Ranbaxy (UK) Limited

Gabapentin 100mg Capsules

PL 14894/0530

Batch Number	Expiry Date	Pack Size	First Distributed
2037862	May 2011	1x100	10 Sep 2009

Ranbaxy (UK) Limited is recalling all unused stock of the above batch because the patient Information leaflet (PIL) has not been updated to include safety warnings initiated by the European Medicines Agency. The missing text should be positioned under the heading 'Take special care with' and states the following:

'A small number of people being treated with anti-epileptics such as Gabapentin have had thoughts of harming and killing themselves. If at any time you have these thoughts, immediately contact your doctor'

The PIL in subsequent batches of the product has been updated.

Pharmacists are asked to quarantine all remaining stock of the above batch and return it to the wholesaler from which it was purchased. For any stock enquiries please contact Ranbaxy (UK) Limited on 0208 742 5299.

For medical information enquiries, please contact Ranbaxy (UK) limited on 0208 742 5292.

MHRA Distribution:

Regional Contacts for NHS Trusts and Provider Units

Chief Pharmacists: England, Scotland, Wales, Northern Ireland

Prison Health Policy Unit (DH)

Chief Pharmacists: Jersey, Guernsey, Alderney, Sark, Isle of Man, Gibraltar

Special Hospitals

Healthcare Commission for distribution to Independent Health Care Establishments

Primary Care Trusts (England)

Medicines and Healthcare products Regulatory Agency

Market Towers 1 Nine Elms Lane London SW8 5NQ

T 020 7084 2000 F 020 7084 2353 www.mhra.gov.uk

An executive agency of the Department of Health

Date: 02 June 2010

EL (10)A/12

MDR 40-02/10

Recipients of this Drug Alert should bring it to the attention of relevant contacts by copy of this letter. Primary Care Trusts are asked to forward this to relevant clinics, General Practitioners and Community Pharmacists.

Yours faithfully

Alison Bunce
Pharmaceutical Assessor, DMRC